Blue Cross of Idaho Logo

Express Sign-on

Thank you for registering with Blue Cross of Idaho

If you are an Individual or Family Member, please register here.

If you are a Medicare Advantage or Medicare Supplement member, please register here.

 

MP 2.04.65 Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease

Medical Policy    
Section
Medicine 
Original Policy Date
06/2010
Last Review Status/Date
Reviewed with literature search/9:2014
Issue
9:2014
  Return to Medical Policy Index

Disclaimer

Our medical policies are designed for informational purposes only and are not an authorization, or an explanation of benefits, or a contract.  Receipt of benefits is subject to satisfaction of all terms and conditions of the coverage.  Medical technology is constantly changing, and we reserve the right to review and update our policies periodically. 


Description

LDL have been identified as the major atherogenic lipoproteins and have long been identified by the National Cholesterol Education Project (NCEP) as the primary target of cholesterol-lowering therapy. LDL particles consist of a surface coat composed of phospholipids, free  cholesterol, and apolipoproteins surrounding an inner lipid core composed of cholesterol ester and triglycerides. Traditional lipid risk factors such as LDL-cholesterol (LDL-C), while predictive on a population basis, are weaker markers of risk on an individual basis. Only a minority of subjects with elevated LDL and cholesterol levels will develop clinical disease, and up to 50% of cases of coronary artery disease (CAD) occur in subjects with ‘normal’ levels of total and LDL-C. Thus, there is considerable potential to improve the accuracy of current cardiovascular risk prediction models.

Other nonlipid markers have been identified as having an association with cardiovascular disease including B-type natriuretic peptide, cystatin C, fibrinogen, and leptin. These biomarkers may have a predictive role in identifying cardiovascular disease risk or in targeting for therapy.

Apolipoprotein B

Apolipoprotein B (apo B) is the major protein moiety of all lipoproteins except for HDL. The most abundant form of apo B, large B or B100, constitutes the apo B found in LDL and very-low-density lipoproteins (VLDL). Because both LDL and VLDL each contain 1 molecule of apo B, measurement of apo B reflects the total number of these atherogenic particles, 90% of which are LDL. Because LDL particles can vary both in size and in cholesterol content, for a given concentration of LDL-C, there can be a wide variety of both size and numbers of LDL particles. Thus, it has been postulated that apo B is a better measure of the atherogenic potential of serum LDL than is LDL concentration.

Two basic techniques are used for measuring LDL particle concentration. Particle size can be determined by gradient gel electrophoresis, or direct measurement of the number of LDL particles can be performed using nuclear magnetic spectroscopy. Nuclear magnetic resonance (NMR) spectroscopy is based on the fact that lipoprotein subclasses of different size broadcast distinguishable NMR signals. Thus NMR can  quantify the number of LDL particles of a specific size (ie, small dense LDL) and can provide a measurement of the total number of particles.

Apolipoprotein AI

HDL contains 2 associated apolipoproteins, ie, AI and AII. HDL particles can also be classified by whether they contain apolipoprotein AI (apo AI) only or whether they contain both apo AI and apolipoprotein AII (apo AII). All lipoproteins contain apo AI, and some also contain apo AII. Because all HDL particles contain apo AI, this lipid marker can be used as an approximation for HDL number, similar to the way apo B has been proposed as an approximation of the LDL number.

Direct measurement of apo AI has been proposed as more accurate than the traditional use of HDL level in evaluation of the cardioprotective, or “good,” cholesterol. In addition, the ratio of apo B/apo AI has been proposed as a superior measure of the ratio of proatherogenic (ie, “bad”) cholesterol to anti-atherogenic (ie, “good”) cholesterol.

Apolipoprotein E

Apolipoprotein E (apo E) is the primary apolipoprotein found in VLDLs and chylomicrons. Apo E is the primary binding protein for LDL receptors in the liver and is thought to play an important role in lipid metabolism. The apolipoprotein E (APOE) gene is polymorphic, consisting of 3 epsilon alleles (e2, e3, e4) that code for 3 protein isoforms, known as E2, E3, and E4, which differ from one another by 1 amino acid. These molecules mediate lipid metabolism through their different interactions with the LDL receptors. The genotype of apo E alleles can be assessed by gene amplification techniques, or the APOE phenotype can be assessed by measuring plasma levels of apo E.

It has been proposed that various APOE genotypes are more atherogenic than others and that APOE measurement may provide information on risk of CAD above traditional risk factor measurement. It has also been proposed that the APOE genotype may be useful in the selection of specific components of lipid-lowering therapy, such as drug selection. In the major lipid-lowering intervention trials, including trials of statin therapy, there is considerable variability in response to therapy that cannot be explained by factors such as compliance. APOE genotype may be 1 factor that determines an individual’s degree of response to interventions such as statin therapy.

B-Type or Brain Natriuretic Peptide

Brain natriuretic peptide (BNP) is an amino acid polypeptide that is secreted primarily by the ventricles of the heart when pressure to the cardiac muscles increases or there is myocardial ischemia. Elevations in BNP levels reflect deterioration in cardiac loading levels and may predict adverse events. BNP has been studied as a biomarker for managing heart failure and predicting cardiovascular and heart failure risk.

Cystatin C

Cystatin C is a small serine protease inhibitor protein that is secreted from all functional cells found throughout the body. It has primarily been used as a biomarker of kidney function. Cystatin C has also been studied to determine whether it may serve as a biomarker for predicting cardiovascular risk. Cystatin C is encoded by the CST3 gene.

Fibrinogen

Fibrinogen is a circulating clotting factor and precursor of fibrin. It is important in platelet aggregation and a determinant of blood viscosity. Fibrinogen levels have been shown to be associated with future risk of cardiovascular risk and all-cause mortality.

HDL Subclass

HDL particles exhibit considerable heterogeneity, and it has been proposed that various subclasses of HDL may have a greater role in protection from atherosclerosis. Particles of HDL can be characterized based on size/density and/or on the apolipoprotein composition. Using size/density, HDL can be classified into HDL2, the larger, less dense particles that may have the greatest degree of cardioprotection, and HDL3, which are smaller, denser particles. HDL contains 2 associated apolipoproteins, ie, AI and AII. HDL particles can also be classified by whether they contain apo AI only or whether they contain both apo AI and apo AII. There has been substantial interest in determining whether subclasses of HDL can be used to provide additional information on cardiovascular risk compared to HDL alone.

An alternative to measuring the concentration of subclasses of HDL, such as HDL2 and HDL3, is direct measurement of HDL particle size and/or number. Particle size can be measured by NMR spectroscopy or by gradient-gel electrophoresis. HDL particle numbers can be measured by NMR spectroscopy. Several commercial labs offer these measurements of HDL particle size and number. Measurement of apo AI has used measurement of HDL particle number as a surrogate, based on the premise that each HDL particle contains 1 apo AI molecule.

LDL Subclass

Two main subclass patterns of LDL, called A and B, have been described. In subclass pattern A, the particles have a diameter larger than 25 nm and are less dense, while in subclass pattern B, the particles have a diameter less than 25 nm and a higher density. Subclass pattern B is a commonly inherited disorder associated with a more atherogenic lipoprotein profile, also termed “atherogenic dyslipidemia.” In addition to small, dense LDL, this pattern includes elevated levels of triglycerides, elevated levels of apo B, and low levels of HDL. This lipid profile is commonly seen in type II diabetes and is 1 component of the “metabolic syndrome,” defined by the Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III [ATP III]) to also include high normal blood pressure, insulin resistance, increased levels of inflammatory markers such as C-reactive protein (CRP), and a prothrombotic state. Presence of the metabolic syndrome is considered by ATP III to be a substantial risk-enhancing factor for CAD.

LDL size has also been proposed as a potentially useful measure of treatment response. Lipid-lowering treatment decreases total LDL and may also induce a shift in the type of LDL, from smaller, dense particles to larger particles. It has been proposed that this shift in lipid profile  may be beneficial in reducing risk for CAD independent of the total LDL level. Also, some drugs may cause a greater shift in lipid profile than others. Niacin and/or fibrates may cause a greater shift from small to large LDL size than statins. Therefore, measurement of LDL size may potentially play a role in drug selection or may be useful in deciding to use a combination of 2 or more drugs rather than a statin alone.

In addition to the size of LDL particles, interest has been shown in assessing the concentration of LDL particles as a distinct cardiac risk factor. For example, the commonly performed test, LDL-C is not a direct measure of LDL but, chosen for its convenience, measures the amount of cholesterol incorporated into LDL particles. Because LDL particles carry much of the cholesterol in the bloodstream, the concentration of cholesterol in LDL correlates reasonably well with the number of LDL particles when examined in large populations. However, for an individual patient, the LDL-C level may not reflect the number of particles due to varying levels of cholesterol in different sized particles. It is proposed that the discrepancy between the number of LDL particles and the serum level of LDL-C represents a significant source of unrecognized atherogenic risk. The size and number of particles are interrelated. For example, all LDL particles can invade the arterial wall and initiate atherosclerosis. However, small, dense particles are thought to be more atherogenic compared with larger particles. Therefore, for patients with elevated numbers of LDL particles, cardiac risk may be further enhanced when the particles are smaller versus larger.

Two techniques are most commonly used for measuring LDL particle concentration, the surrogate measurement of apo B or direct measurement of the number of particles using NMR. NMR is used based on the fact that lipoprotein subclasses of different size broadcast distinguishable NMR signals. Thus NMR can directly measure the number of LDL particles of a specific size (ie, small dense LDL) and can provide a measurement of the total number of particles. Thus, NMR is proposed as an additional technique to assess cardiac risk.

Leptin

Leptin is a protein secreted by fat cells that has been found to be elevated in heart disease. Leptin has been studied to determine if it has any relationship with the development of cardiovascular disease.

Lipoprotein A

Lipoprotein (a) (lp[a]) is a lipid-rich particle similar to LDL. apo B is the major apolipoprotein associated with LDL; in lp(a), however, there is an additional apo A covalently linked to the apo B. The apolipoprotein (a) molecule is structurally similar to plasminogen, suggesting that lp(a) may contribute to the thrombotic and atherogenic basis of cardiovascular disease. Levels of lp(a) are relatively stable in individuals over time but vary up to 1000-fold between individuals, presumably on a genetic basis. The similarity between lp(a)and fibrinogen has stimulated intense interest in lp(a) as a link between atherosclerosis and thrombosis. In addition, approximately 20% of patients with CAD have elevated levels of lp(a). Therefore, it has been proposed that levels of lp(a) may be an independent risk factor for CAD.

For testing performed as a panel, see Medical Policy Reference Manual Policy No. 2.04.100.


Policy  

 

Measurement of novel lipid and nonlipid risk factors (ie, apolipoprotein B, apolipoprotein AI, apolipoprotein E, B-type natriuretic peptide, cystatin C, fibrinogen, leptin, LDL subclass, HDL subclass, lipoprotein[a]) is considered investigational as an adjunct to LDL cholesterol in the risk assessment and management of cardiovascular disease.


Policy Guidelines

There is no specific CPT code for measurement of apolipoprotein B. CPT code 82172 (apolipoprotein, each) might be used.

There is no specific code for apo E phenotyping or genotyping. For phenotyping, CPT code 84181 (Protein; Western blot) may be used. Effective in 2012, testing for APOE common variants can be reported using CPT code 81401.

There is no CPT code for subclassification that is specific to high-density lipoprotein (HDL). CPT code 82664 (electrophoretic technique, not otherwise specified) or 83701 (lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed [eg, electrophoresis, ultracentrifugation]) may be used.

There is a CPT code for lipoprotein particle number and subclass quantification by nuclear magnetic resonance spectroscopy that is also not specific to HDL: 83704: Lipoprotein, blood; quantification of lipoprotein particle numbers and lipoprotein particle subclasses (eg., by nuclear magnetic resonance spectroscopy)

Effective in 2006, the following CPT codes for quantitation of lipoprotein levels are available:

83700 Lipoprotein, blood; electrophoretic separation and quantitation
83701 high resolution fractionation and quantitation of lipoprotein subclasses when performed (eg, electrophoresis, ultracentrifugation)
83704 quantitation of lipoprotein particle numbers and lipoprotein particle subclasses (eg, by nuclear magnetic resonance spectroscopy)

There is a specific CPT code for lipoprotein (a) testing:
83695: Lipoprotein (a)

There is a specific CPT code for B-type natriuretic peptide testing:
83880: Natriuretic peptide.

Testing for cystatin C is reported with CPT code 82610 (Cystatin C).

There are 2 CPT codes for fibrinogen testing:
85384: Fibrinogen; activity
85385: antigen

There is no specific CPT code for leptin testing. According to laboratory websites, CPT codes such as 82397 (Chemiluminescent assay) or 83520 (Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified) might be used.


Benefit Application
BlueCard/National Account Issues

 

Determination of novel lipid risk factors (apolipoprotein B, apolipoprotein AI, apolipoprotein E, LDL subclass, HDL subclass, lipoprotein (a)) may be offered as a component of a comprehensive cardiovascular risk assessment offered by reference laboratories. Comprehensive risk assessment may include evaluation of small LDLs, subclassification of HDLs, evaluation of apolipoprotein E genotype or phenotype, total plasma homocysteine, lipoprotein (a), high-sensitivity C-reactive protein, and homocysteine levels.


Rationale

A large body of literature has accumulated on the utility of novel lipid risk factors in the prediction of future cardiac events. The evidence reviewed for this policy statement consists of systematic reviews, metaanalyses and large, prospective cohort studies that have evaluated the association of these lipid markers with cardiovascular outcomes. A smaller amount of literature is available on the utility of these markers as a marker of treatment response. Data on treatment response is taken from randomized controlled trials (RCTs) that use 1 or more novel lipid markers as a target of lipid-lowering therapy.

The ATP III guidelines document(1) notes that to determine their clinical significance, the emerging risk factors should be evaluated against the following criteria to determine their clinical significance:

  • Significant predictive power that is independent of other major risk factors
  • A relatively high prevalence in the population (justifying routine measurement in risk assessment)
  • Laboratory or clinical measurement must be widely available, well standardized, inexpensive, have accepted population reference values, and be relatively stable biologically
  • Preferable, but not necessarily, modification of the risk factor in clinical trials will have shown reduction in risk.

A 2002 TEC Assessment(2) summarized the steps necessary to determine utility of a novel cardiac risk factor. Three steps were required:

  • Standardization of the measurement of the risk factor.
  • Determination of its contribution to risk assessment. As a risk factor, it is important to determine whether the novel risk factor […] independently contributes to risk assessment compared with established risk factors.
  • Determination of how the novel risk assessment will be used in the management of the patient, compared with standard methods of assessing risk, and whether any subsequent changes in patient management result in an improvement in patient outcome.

Each of the individual novel lipid risk factors will be judged individually against these criteria to determine whether health outcomes are improved through measurement of the novel lipid risk factor.

Systematic Reviews and Meta-analyses

Thanassoulis et al in 2014 reported on a meta-analysis of 7 placebo-controlled statin trials to evaluate the relationship of statin-induced reductions in lipid levels to reduction of coronary heart disease risk.(3) Each of the trials included -density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein-cholesterol (HDL-C), and apolipoprotein B (apo B) values assessed at baseline and 1-year follow-up. In both frequentist and Bayesian meta-analyses, reductions in apo B were more closely related to coronary heart disease risk reduction from statins than LDL-C or non-HDL-C.

In 2013, van Holten et al reported on a systematic review of 85 articles with 214 meta-analyses to compare serological biomarkers for risk of cardiovascular disease (CVD).(4) Predictive potential for primary CVD events was strongest with lipids with a ranking from high to low found with: C-reactive protein (CRP), fibrinogen, cholesterol, apo B, the apolipoprotein A (apo A)/apo B ratio, HDL, and vitamin D. Markers associated with ischemia were more predictive of secondary cardiovascular events and included from high to low result: cardiac troponins I and T, C-reactive protein (CRP), serum creatinine, and cystatin C. A strong predictor for stroke was fibrinogen.

Tzoulaki et al, in 2013, reported on an evaluation of meta-analyses on biomarkers for CVD risk to examine potential evidence of bias and inflation of result in the literature.(5) Included in the evaluation were 56 meta-analyses with 49 reporting statistically significant results. Very large heterogeneity was seen in 9 meta-analyses, and small study effects were seen in 13 meta-analyses. Significant excess of studies with statistically significant results was found in 29 meta-analyses (52%). The authors report only 13 of the meta-analyses with statistically significant results had more than 1000 cases and no evidence of large heterogeneity, small-study effects, or excess significance.

In a 2013 systematic review, Willis et al evaluated whether validated CVD risk scores can identify patients at risk for CVD for participation in more intensive intervention programs for primary prevention.(6) Sixteen papers on 5 studies were included in the systematic review. The authors were unable to perform a metaanalysis due to the heterogeneity of the studies. The evidence was considered not strong enough to draw definitive conclusions, but the authors note lifestyle interventions with higher intensity may have potential for lowering CVD risk.

Apolipoprotein B

Apo B as a Predictor of Cardiovascular Risk

In 2013 Robinson et al published results of a Bayesian random-effects meta-analysis of RCTs to compare the effectiveness of lowering apo B versus LDL-C and non-HDL-C for reducing CVD, coronary heart disease and stroke risk.(7) Included in the analysis were 131,134 patients from 25 RCTs including 12 trials on statins, 5 on niacins, 4 on fibrates, 1 on simvastatin–ezetimibe, 1 on aggressive versus standard LDL and blood pressure targets and 1 on ileal bypass surgery. In the analysis of all trials, each apo B
decrease of 10 mg/dL resulted in a 6% decrease in major CVD risk and a 9% decrease in coronary heart disease risk prediction, but stroke risk was not decreased. Decreased apo B levels were not superior to decreased non-HDL in decreasing CVD (Bayes factor [BF], 2.07) and coronary heart disease risk (BF=1.45) prediction. When non-HDL-C plus LDL-C decrease were added to apo B decrease, CVD risk prediction improved slightly (BF=1.13) but not coronary heart disease risk prediction (BF=1.03) and stoke risk prediction worsened (BF=0.83). In summary, the addition of apo B decrease did not consistently add information to LDL, non-HDL or LDL/non-HDL decreases to improve CVD risk prediction when analyzed across lipid-modifying treatments of all types. Sniderman et al reported on 9345 acute myocardial infarction patients compared with 12,120 controls in the standardized case-control INTERHEART study.(8) The authors reported discordance in the levels of cholesterol contained in apo B and non-HDL-C. In contrast to the Robinson study previously mentioned, apo B was found to be more accurate than non-HDL-C as a marker for cardiovascular risk.

The Emerging Risk Factors Collaboration published a patient-level meta-analysis of 37 prospective cohort studies enrolling 154,544 patients.(9) Risk prediction was examined for a variety of traditional and nontraditional lipid markers. For apo B, evidence from 26 studies on 139,581 subjects reported that apo B was an independent risk factor for cardiovascular events, with an adjusted hazard ratio (HR) of 1.24 (95% confidence interval [CI], 1.19 to 1.29). On reclassification analysis, when apo B and apo AI were substituted for traditional lipids, there was not improvement in risk prediction. In fact, there was a slight worsening in the predictive ability, evidenced by a decrease in the C statistic of -0.0028 (p<0.001), and a decrease in the net reclassification improvement of -1.08% (p<0.01).

The Quebec Cardiovascular Study10 evaluated the ability of levels of apo B and other lipid parameters to predict subsequent coronary artery disease (CAD) events in a prospective cohort study of 2155 men followed up for 5 years. Elevated levels of apo B were found to be an independent risk factor for ischemic heart disease after adjustment for other lipid parameters (risk ratio [RR], 1.40; 95% CI, 1.2 to 1.7). In patients with an apo B level of greater than 120 mg/dL, there was a 6.2-fold increase in the risk of cardiovascular events.

The Apolipoprotein Mortality Risk Study (AMORIS)(11) was another prospective cohort study that followed up 175,000 Swedish men and women presenting for routine outpatient care over a mean of 5.5 years. This study found that apo B was an independent predictor of CAD events and was superior to LDL-C levels in predicting risk, both for the entire cohort and in all subgroups examined. Risk ratios for the highest quartile of apo B levels were 1.76 in men (p<0.001) and 1.69 in women (p<0.001).

A cohort study of 15,632 participants from the Women’s Health Initiative(12) provided similar information in women. In this analysis, the hazard ratio for developing coronary heart disease in the highest versus the lowest quintiles was greater for apo B (2.50; 95% CI, 1.68 to 3.72) compared with LDL-C (1.62; 95% CI, 1.17 to 2.25), after adjustment for traditional cardiovascular risk factors.

The Copenhagen City Heart Study(13) was a prospective cohort study of 9231 asymptomatic persons from the Danish general population followed up for 8 years. Subjects with total apo B levels in the top one-third (top tertile) had a significantly increased relative risk of cardiovascular events compared with patients in the lowest one-third, after controlling for LDL-C and other traditional cardiovascular risk factors (RR=1.4; 95% CI, 1.1 to 1.8 for men; RR=1.5; 95% CI, 1.1 to 2.1 for women). This study also compared the discriminatory ability of apo B with that of traditional lipid measures, by using the area under the curve (AUC) for classifying cardiovascular events. Total apo B levels had a slightly higher AUC compared with LDL-C (0.58 vs 0.57, respectively); however this difference in AUC was not statistically significant.

At least 1 large prospective cohort study, the Atherosclerosis Risk in Communities (ARIC) study,(14) concluded that apo B did not add additional predictive information above standard lipid measures. The ARIC study followed up 12,000 middle-aged people free of CAD at baseline for 10 years. While apo B was a strong univariate predictor of risk, it did not add independent predictive value above traditional lipid measures in multivariate models.

The ratio of apo B/apo AI has also been proposed as a superior measure of the ratio of proatherogenic (ie, “bad”) cholesterol to anti-atherogenic (ie, “good”) cholesterol. This ratio may be a more accurate measure of this concept, compared to the more common total cholesterol (TC)/HDL (TC/HDL) ratio. A number of epidemiologic studies have reported that the apo B/apo AI ratio is superior to other ratios, such as TC/HDL-C, or non-HDL-C/HDL-C.(15,16)

Kappelle et al17 used data from the prospective PREVEND cohort to evaluate the predictive value of the apo B/apo AI ratio independent of other traditional risk factors, including albuminuria and CRP. Among 6948 subjects without previous heart disease and who were not on lipid-lowering drugs, the adjusted hazard ratio for a high apo B/apo AI ratio was 1.37 (95% CI, 1.26 to 1.48). This hazard ration was not significantly different from the TC/HDL-C ratio of 1.24 (95% CI, 1.18 to 1.29), and was not significantly changed after further adjustment for triglycerides.

Some studies have tested the use of apo B in a multivariate risk prediction model in which both traditional risk factors and apolipoprotein measures were included as potential predictors. Ridker et al(18) published the Reynolds Risk Score, based on data from 24,558 initially healthy women enrolled in the Women’s Health Study and followed up for a median of 10.2 years. A total of 35 potential predictors of CVD were considered as potential predictors, and 2 final prediction models were derived. The first model was the best fitting model statistically, and included both apo B and the apo B/apo AI ratio as 2 of 9 final predictors. The second model, called the “clinically simplified model,” substituted LDL-C for apo B and total/HD) cholesterol for apo B/apo AI. The authors developed this simplified model “for the purpose of clinical application and efficiency” and justified replacing the apo B and apo B/apo AI measures as a result of their high correlation with traditional lipid measures (r=0.87 and 0.80, respectively).

Ingelsson et al(19) used data from 3322 subjects in the Framingham Offspring Study to compare prediction models with traditional lipid measures to models that include apolipoprotein and other nontraditional lipid measures. This study reported that the apo B/apo AI ratio had similar predictive ability as traditional lipid ratios with respect to model discrimination, calibration, and reclassification. The authors also reported that the apo B/apo AI ratio did not provide any incremental predictive value over traditional measures.

Apo B as a Treatment Target

A number of RCTs of statin therapy have examined the change in apo B on treatment in relation to clinical CAD outcomes and compared whether apo B is a better predictor of outcomes when compared with LDL-C.

Boekholdt et al(20) published an individual patient-level meta-analysis of on-treatment levels of traditional and nontraditional lipids as a measure of residual risk. A total of 8 studies enrolling 62,154 participants were included. The adjusted HR for each 1 SD increase in apo B was 1.14 (95% CI, 1.11 to 1.18), which was not significantly different from LDL-C (HR=1.13; 95% CI, 1.10 to 1.17; p=0.21). The HR for HDL-C was 1.16 (95% CI, 1.12 to 1.19), which was significantly greater than LDL-C or apo B (p=0.002). In a subsequent report from this meta-analysis, Boekholdt et al21 evaluated the LDL-C, non-HDL-C, and apo B levels of 38,153 patients allocated to the statin therapy groups. Despite statin therapy, reductions in levels of LDL-C, non-HDL-C, and apo B from baseline to 1 year showed large interindividual variation.

In 2013, Ballantyne et al reported on a post hoc analysis of 682 patients with acute coronary syndrome from the randomized, phase 3 study Limiting Undertreatment of Lipids in Acute Coronary Syndrome with Rosuvastatin (LUNAR) study. The LUNAR subanalysis examined apo B in relation to LDL-C and non-HDL-C under intensive statin therapy with rosuvastatin or atorvastatin.(22) The treatment target for apo B of 80 mg/dL correlated with LDL-C of 90 mg/dL and non-HDL-C of 110 mg/dL at baseline and with LDL-C of 74 mg/dL and non-HDL-C of 92 mg/dL with statin therapy. Independent of triglyceride status, non-HDL-C was found to have a stronger correlation with apo B than LDL-C and could be an adequate surrogate of apo B during statin therapy.

The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) evaluated lipid parameters among 6605 men and women with average LDL- and low HDL-C levels who were randomly assigned to receive either lovastatin or placebo.(23) Baseline LDL-C and HDL-C, as well as levels of apo B, were predictive of future coronary events. However, in the treatment group, post-treatment levels of LDL-C and HDL-C were not predictive of subsequent risk, while posttreatment apo-B levels were predictive.

In the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) trial,(24) the relationship of ontreatment apo B levels to clinical outcomes was examined in 9140 patients randomized to pravastatin or placebo and followed up for a mean of 6.1 years. The adjusted HR for apo B levels (2.10; 95% CI, 1.21 to 3.64, p=0.008) was higher than that for LDL-C (1.20; 95% CI, 1.00 to 1.45; p=0.05). Also, the proportion of the treatment effect explained by on-treatment apo B levels (67%) was higher than that for LDL-C levels (52%).

Kastelein et al(25) combined data from 2 RCTs, the Treating to New Targets (TNT) and Incremental Decrease in End Points through Aggressive Lipid Lowering (IDEAL) trials, to compare the relationship between response to lipids, apo B levels, and other lipid measures. This analysis included 18,889 patients with established coronary disease randomly assigned to low- or high-dose statin treatment. In pairwise comparisons, the on-treatment apo B level was a significant predictor of cardiovascular events (HR=1.24; 95% CI, 1.13 to 1.36; p<0.001), while LDL level was not. Similarly, the ratio of apo B/apo AI was a significant predictor of events (HR=1.24; 95% CI, 1.17 to 1.32), while the total/HDL-C was not. In another publication that reported on the TNT study,(26) the on-treatment apo B level was also a significant predictor of future events (adjusted HR=1.19; 95% CI, 1.11 to 1.28). In this study, the known baseline variables performed well in discriminating future cases from noncases, and the addition of apo B was not associated with additional risk.

Mora et al(27) measured on-treatment lipid levels to assess the prediction of residual risk while on statin therapy. Using data from the JUPITER trial, on-treatment levels of LDL-C, non-HDL-C, high-sensitivity (hs)-CRP, apo B, and apo AI were used to predict subsequent cardiovascular events. The HRs for cardiovascular events were similar among all the lipid measures, ranging from 1.22 to 1.31, with no significant differences between measures. The residual risk declined overall with a decreasing level of
LDL-C, with the lowest risk seen in subjects achieving an LDL-C of less than 70mg/dL.

Current Treatment Guidelines

The ATP III guidelines1 identify apo B as an “emerging risk factor.” In their discussion of apo B, the guidelines state that the apo B level typically is disproportionately higher in persons with hypertriglyceridemia, and that “ATP III takes this difference into account and sets a secondary target, non-HDL-C, in persons with  hypertriglyceridemia. Non-HDL-C is significantly correlated with apolipoprotein B and can serve as a ‘surrogate’ for it. The non-HDL-C measure is readily available in
clinical practice, whereas standardized apolipoprotein B measures are not widely available.”

In 2004, the American College of Physicians published clinical practice guidelines regarding lipid control in the management of type 2 diabetes.(28) These guidelines do not address the role of measurement of either apo B or direct measurements of lipid particle concentration. In July 2004, Grundy et al published an article outlining the implications of clinical trials of statin therapy that were published after ATP III.(29) The authors recommended a further lowering of the target LDL-C for some populations of patients. For example, the LDL-C target of 100 mg/dL in high-risk patients was lowered to 70 mg/dL, and the target in moderately high-risk patients was lowered from 130 to 100. These more aggressive targets of therapy create additional questions of how measurements of apo B can be used to improve patient management.

A publication from a consensus conference of the American Diabetes Association and the American College of Cardiology Foundation(30) included specific  recommendations for incorporating apo B testing into clinical care for high-risk patients. This expert panel stated that “ApoB and LDL particle number also
appear to be more discriminating measures of the adequacy of LDL lowering therapy than are LDL cholesterol or non-HDL cholesterol.” They therefore recommend that for patients with metabolic syndrome who are being treated with statins, both LDL-C and apo B should be used as treatment targets, with an apo B target of less than 90 mg/dL. Treatment should be intensified for patients with apo B above this level, even if target LDL has been achieved.

A Canadian task force has also endorsed use of apo B as a treatment target and proposed a target apo B level of 90 mg/dL.(31) Other experts have recommended using a lower target of 80 mg/dL for apo B.(32) However, none of the major guideline entities in the United States, such as ATP III, have incorporated apo B targets as part of their formal recommendations.

Section Summary

The evidence suggests that apo B provides independent information on risk assessment for cardiovascular disease and that apo B may be superior to LDL-C in predicting cardiovascular risk. Numerous large prospective cohort studies and nested case-control studies have compared these measures, and most have concluded that apo B is a better predictor of cardiac risk when compared with LDL-C. However, some meta-analyses have concluded that apo B is not a better predictor of cardiac risk than HDL or non-HDL combined with LDL. There is also greater uncertainty around the degree of improvement in risk prediction and whether the magnitude of improvement is clinically significant. While there have been attempts to incorporate apo B into multivariate risk prediction models, at the present time, apo B is not included in the models that are most commonly used in routine clinical care, such as the Framingham risk model and the Prospective Cardiovascular Munster Study (PROCAM) Score.

Furthermore, as a marker of response to cholesterol-lowering treatment, apo B may be more accurate than LDL-C and may provide a better measure of the adequacy of antilipid therapy than does LDL-C. Post hoc analyses of RCTs of statin treatment have reported that on-treatment levels of apo B are more highly correlated with clinical outcomes than standard lipid measures. Whether the degree of improvement in assessing treatment response is clinically significant has yet to be determined.

Some experts currently believe that the evidence is sufficient to warrant the routine clinical use of apo B levels as a replacement for LDL-C levels and the use of the apo B/apo AI ratio as a replacement for the TC/HDL-C ratio. These experts argue that the use of apo B in place of LDL-C will allow better targeting of antilipid therapy and avoid undertreatment in a substantial number of patients with low or normal LDL levels and small, dense subtype (high apo B). As of the current time, none of the major guidelines, such as ATP III, have yet to formally incorporate the measurement of apo B into their recommendations. Additionally, the LUNAR study subanalysis found apo B strongly correlates with non-HDL and may be used as an appropriate surrogate in place of apo B in targeting treatment goals.

However, it is not yet possible to conclude that the use of apo B levels will improve outcomes when used in routine clinical care. Improved ability to predict risk and/or treatment response does not by itself result in better health outcomes. To improve outcomes, clinicians must have the tools to translate this information into clinical practice. No studies have demonstrated improved health outcomes by using apo B in place of LDL-C for either risk assessment and/or treatment response. The most widely used risk assessment models, such as the Framingham prediction model, and the most widely used treatment guidelines, the ATP III guidelines, do not provide the tools necessary for clinicians to incorporate apo B measurements into routine assessment and management of hyperlipidemic patients. This lack creates difficulties in interpreting and applying the results of apo B and/or apo B/apo AI measurements to routine clinical care.

Therefore, based on review of the currently available evidence, this testing is considered investigational.

Apolipoprotein AI

Apo AI as a Predictor of Cardiovascular Disease

The Emerging Risk Factors Collaboration published a patient-level meta-analysis of 37 prospective cohort studies enrolling 154,544 subjects.(9) Risk prediction was examined for a variety of traditional and nontraditional lipid markers. For apo AI, evidence from 26 studies on 139,581subjects reported that apo AI was an independent risk factor for reduced cardiovascular risk, with an adjusted HR for cardiovascular events of 0.87 (95% CI, 0.84 to 0.90). On reclassification analysis, when apo B and apo AI were substituted for traditional lipids, there was not improvement in risk prediction. In fact, there was a slight worsening in the predictive ability, evidenced by a decrease in the C statistic of -0.0028 (p<0.001) and a decrease in the net reclassification improvement of -1.08% (p<0.01).

The Apolipoprotein-Related Mortality Risk Study (AMORIS) followed up 175,000 Swedish men and women for 5.5 years(11) and reported that decreased apo AI was an independent predictor of coronary artery disease (CAD) events. The AFCAPS/TexCAPS investigated lipid parameters among 6605 men and women with average LDL-C and low HDL-C who were randomized to receive either lovastatin or placebo.(23) This study also reported that levels of apo AI, as well as the ratio of apo B/apo AI, were strong predictors of CAD events.

The Copenhagen City Heart Study(13) was a prospective cohort study of 9231 asymptomatic persons from the Danish general population. The apo B/apo AI ratio was reported to be an independent predictor of cardiovascular events, with a HR similar to that for TC/HDL-C. This study also compared the discriminatory ability of the apo B/apo AI ratio with that of traditional lipid measures, with use of the AUC for classifying cardiovascular events. The apo B/apo AI ratio had a slightly higher AUC when compared with TC/HDL-C ratio (0.59 vs 0.58, respectively), but this difference was not statistically significant.

Clarke et al(33) published a prospective cohort study of 7044 elderly men enrolled in the Whitehall Cardiovascular Cohort from London, England. Measurements of apolipoprotein levels were performed on 5344 of these patients, and patients were followed up for a mean of 6.8 years. The authors reported that the apo B/apo AI ratio was also a significant independent predictor (HR=1.54; 95% CI, 1.27 to 1.87), with similar predictive ability compared with the TC/HDL ratio (HR=1.57; 95% CI, 1.32 to 1.86).

The addition of the apo B/apo AI ratio to the Framingham risk model(34) resulted in a statistically significant improvement in predictive value for cardiovascular events (AUC 0.594 vs AUC 0.613, respectively; p<001). However, the authors concluded that this increment in predictive value was likely to be of little clinical value. This same study also reported the predictive ability of apo AII in a separate publication. In this analysis, subjects with apo AII levels in the highest quartile had a decreased risk of cardiovascular events compared with those in the lowest quartile (adjusted odds ratio [OR], 0.62; 95% CI, 0.43 to 0.90).

Ridker et al(18) compared the predictive ability of apo AI and the ratio of apo B/apo AI with standard lipid standard lipid measurements but were no better. The HR for future cardiovascular events was 1.75 (95% CI, 1.30 to 2.38) for apo AI, compared with 2.32 (95% CI, 1.64 to 3.33) for HDL-C. The HR for the ratio of apo B/apo AI was 3.01 (95% CI, 2.01 to 4.50), compared with a HR of 3.18 (95% CI, 2.12 to 4.75) for the ratio of LDL-C/HDL-C.

Some researchers have attempted to develop multivariate risk prediction models intended for use in clinical care, in which both traditional risk factors and apolipoprotein measures were included as potential predictors. Ridker et al(18) published the Reynolds Risk Score, based on data from 24,558 initially healthy women enrolled in the Women’s Health Study and followed up for a median of 10.2 years. A total of 35 potential predictors of cardiovascular disease were considered potential predictors, and 2 final prediction models were derived. The first model was the best-fitting model statistically and included both apo B and the apo B/apo AI ratio as 2 of 9 final predictors. The second model, called the “clinically simplified model,” substituted LDL-C for apo B and TC/HDL-C for apo B/apo AI. The authors developed this simplified model “for the purpose of clinical application and efficiency” and justified replacing the apo B and apo B/apo AI measures as a result of their high correlation with traditional lipid measures (r=0.87 and 0.80, respectively).

Ingelsson et al(19) used data from 3322 individuals in the Framingham Offspring Study to compare prediction models with traditional lipid measures to models that include apolipoprotein and other nontraditional lipid measures. This study reported that the apo B/apo AI ratio had similar predictive ability compared with traditional lipid ratios with respect to model discrimination, calibration, and reclassification. The authors also reported that the apo B/apo AI ratio did not provide any incremental predictive value over traditional measures.

A nested case-control study,(35) performed within the larger EPIC-Norfolk cohort study, evaluated the predictive ability of apo B/apo AI in relation to traditional lipid measures. The European Prospective Investigation into Cancer and Nutrition-Norfolk (EPIC-Norfolk) study is a cohort study of 25,663 patients from Norfolk, U.K. The case control substudy enrolled 869 patients who had developed CAD during a mean follow-up of 6 years and 1511 control patients without CAD. The authors reported that the apo B/apo AI ratio was an independent predictor of cardiovascular events after controlling for traditional lipid risk factors and the Framingham risk score (adjusted OR=1.85; 95% CI, 1.15 to 2.98). However, the authors also reported that this ratio was no better than TC/HDL ratio for discriminating between cases and controls (AUC, 0.673 vs 0.670, respectively; p=0.38).

Apo A-I as a Treatment Target

A number of studies have evaluated the utility of the apo B/apo AI ratio as a marker of treatment response in RCTs of statin treatment. Kastelein et al(25) combined data from 2 RCTs, the TNT and IDEAL trials, to compare the relationship between response to lipids, apo B/apo AI ratio, and other lipid measures. This analysis included 18,889 patients with established coronary disease randomized to low-or high-dose statin treatment. In pairwise comparisons, the ratio of apo B/apo AI was a significant
predictor of events (HR=1.24; 95% CI, 1.17 to 1.32) while the TC/HDL-C was not.

The PROVE-IT TIMI study36 randomized 4162 patients with acute coronary syndrome (ACS) to standard statin therapy or intensive statin therapy. While the on-treatment ratio of apo B/apo AI ratio was a significant predictor of cardiac events (HR for each SD increment, 1.10; 95% CI, 1.01 to 1.20), it was not superior to LDL-C (HR=1.20; 95% CI, 1.07 to 1.35) or the TC/HDL ratio (HR=1.12; 95% CI, 1.01 to 1.24) as a predictor of cardiac events.

Preliminary studies of infusions of reconstituted apo AI have demonstrated plaque regression in a small number of patients with acute coronary syndrome.(37) Based on this research, there is interest in developing synthetic apo AI mimetic proteins, and such agents are in the drug development stage. These types of agents would likely be targeted for patients with residual cardiac risk following maximal statin therapy, especially patients with low HDL levels.

Section Summary

The current evidence generally supports the contention that measurement of apo AI, and the apo B/apo AI ratio, is as good as or better than currently used lipid measures such as LDL and HDL. Some experts argue that the apo B/apo AI ratio is superior to the LDL/HDL ratio as a predictor of cardiovascular risk and measurements. Measurements of apo AI and the apo B/apo AI ratio had similar predictive ability to should supplement or replace traditional lipid measures as both a risk marker and a treatment target.(38,39) However, there is substantial uncertainty regarding the degree of improvement that these measures provide. The evidence suggests that any incremental improvement in predictive ability over traditional measures is likely to be small and of uncertain clinical significance.

The use of apo AI and the apo B/apo AI ratio as a target of treatment response to statins may also be as good or better than the traditional measure of LDL. However, to improve outcomes, clinicians must have the tools to translate this information into clinical practice. Such tools for linking apo AI to clinical decision making, both in risk assessment and treatment response, are currently not available. apo AI has not been incorporated into quantitative risk assessment models or treatment guidelines that can be used in clinical practice, such as the ATP III.(1) The ATP III practice guidelines continue to tie clinical decision making to conventional lipid measures, such as TC, LDL-C, and HDL-C. Therefore, it is not yet possible to conclude that these measures improve outcomes or that they should be adopted in routine clinical care. There is
continued interest in developing new therapeutic agents that raise HDL, and apo AI mimetics are currently in development for this purpose.

Apolipoprotein E

Apo E as a Predictor of Cardiovascular Disease

A large body of research has established a correlation between lipid levels and the underlying APOE genotype. For example, in population studies, the presence of an apo e2 allele is associated with the lowest cholesterol levels and the apo e4 allele is associated with the highest levels.(40,41)

Numerous studies have focused on the relationship between genotype and physiologic markers of atherosclerotic disease. A number of small- to medium-sized cross-sectional and case-control studies have correlated apo E with surrogate outcomes such as cholesterol levels, markers of inflammation, or carotid intima-media thickness.(42-47) These studies have generally shown a relationship between apo E and these surrogate outcomes. Other studies have suggested that carriers of apo e4 are more likely to develop signs of atherosclerosis independent of TC and LDL-C levels.(48-51)

Some larger observational studies have correlated APOE genotype with clinical disease. The Atherosclerosis Risk in Communities (ARIC) study followed up 12,000 middle-aged subjects free of CAD at baseline for 10 years.(14) This study reported that the e3/2 genotype was associated with carotid artery atherosclerosis after controlling for other atherosclerotic risk factors. Volcik et al reported that APOE polymorphisms were associated with LDL levels and carotid intima-media thickness but were not
predictive of incident CAD.(52)

A meta-analysis published by Bennet et al(53) summarized the evidence from 147 studies on the association of APOE genotypes with lipid levels and cardiac risk. Eighty-two studies included data on the association of apo E with lipid levels, and 121 studies reported the association with clinical outcomes. The authors estimated that patients with the apo e2 allele had LDL levels that were approximately 31% less compared with that in patients with the apo e4 allele. When compared with patients with the apo e3 allele, patients with apo e2 had an approximately 20% decreased risk for coronary events (OR=0.80; 95% CI, 0.70 to 0.90). Patients with the apo e4 had an estimated 6% higher risk of coronary events that was of marginal statistical significance (OR=1.06; 95% CI, 0.99 to 1.13).

Apo E as a Predictor of Response to Therapy

Apo E has been investigated as a predictor of response to therapy by examining apo E alleles in the intervention arm(s) of lipid-lowering trials. Some data suggest that patients with an apo e4 allele may respond better to diet-modification strategies.(54,55) Other studies have suggested that response to statin therapy may vary with APOE genotype and that the e2 allele indicates greater responsiveness to statins.(54,56)

Chiodini et al(57) examined differential response to statin therapy according to APOE genotype, by reanalyzing data from the GISSI study according to APOE genotype. GISSI was an RCT comparing pravastatin with placebo in 3304 Italian patients with previous myocardial infarction (MI). Patients with the apo e4 allele treated with statins had a greater response to treatment as evidenced by lower overall mortality (1.85% vs 5.28%, respectively, p=0.023), while there was no difference in mortality for patients who were not treated with statins (2.81% vs 3.67%, respectively, p=0.21). This study corroborates results reported in previous studies but does not provide evidence to suggest that changes in treatment should be made as a result of APOE genotype.

For the 2009 policy update, additional published studies were identified that evaluated APOE genetic status as a predictor of response to lipid-lowering therapy. Donnelly et al(58) reported on 1383 patients treated with statins from the Genetics of Diabetes Audit and Research in Tayside, Scotland (Go-DARTS) database. The researchers reported on the final LDL levels and percent of patients achieving target LDL according to APOE genetic status. LDL levels following treatment were lower for patients who were homozygous for apo e2, compared with patients homozygous for apo e4 (0.6±0.5 mmol/L vs 1.7±0.3 mmol/L, p<0.001). All patients who were homozygous for apo e2 reached their target LDL level, compared with 68% of patients homozygous for apo e4 (p<0.001).

Vossen et al(59) evaluated response to diet and statin therapy by apo E status in 981 patients with CAD who were enrolled in a cardiac rehabilitation program. These authors reported that patients with an apo e4 allele were more responsive to both diet and statin therapy than were patients with an apo e2 allele. The overall response to treatment was more dependent on baseline LDL levels than APOE genetic status, with 30% to 47% of the variation in response to treatment explained by baseline LDL, compared with only 1% of the variation explained by APOE status.

Section Summary

The evidence suggests that APOE genotype may be associated with lipid levels and CAD but is probably not useful in providing additional clinically relevant information beyond established risk factors. Apo E is considered a relatively poor predictor of CAD, especially when compared with other established and emerging clinical variables and does not explain a large percent of the interindividual variation in TC and LDL levels. Moreover, apo E has not been incorporated into standardized cardiac risk assessment models and was not identified as one of the important “emerging risk factors” in the most recent ATP III recommendations.

The evidence on response to treatment indicates that APOE genotype may be a predictor of response to statins and may allow clinicians to better gauge a patient’s chance of successful treatment, although not all studies are consistent in reporting this relationship. At present, it is unclear how this type of information will change clinical management. Dietary modifications are a universal recommendation for those with elevated cholesterol or LDL levels, and statin drugs are the overwhelmingly preferred agents for lipidlowering therapy. It is unlikely that a clinician will choose alternative therapies, even in the presence of an APOE phenotype that indicates diminished response.

None of the available evidence provides adequate data to establish that APOE genotype or phenotype improves outcomes when used in clinical care. Thus, given the uncertain impact on clinical outcomes, this testing is considered investigational.

B-Type or Brain Natriuretic Peptide

The use of brain natriuretic peptide (BNP) levels for monitoring and managing established heart failure patients has been frequently studied and has demonstrated value. Studies on the use of BNP for determining cardiovascular risk in the asymptomatic population, however, are limited. In the Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research [EISNER] study, Shaw et al evaluated BNP and coronary artery calcium levels in 2458 asymptomatic adults.(60) BNP levels ranging from 40 to 99.9 and 100 pg/m or higher had a 2.2 to 7.5 relative hazard for a cardiovascular event compared with BNP levels of less than 40 pg/ml (p<0.001). Other large population cohort studies have shown a relationship between elevations in BNP levels and future risks of cardiovascular events or heart failure.(61,62) In a cohort study of 5067, Melander et al found adding CRP and BNP to a risk model of conventional factors increased the C statistic for cardiovascular events by 0.007 (p=0.04) and for coronary events by 0.009 (p=0.08). In a cohort study of 3346 patients without heart failure, Wang et al found BNP levels above the 80th percentile (20.0 pg/mL for men, 23.3 pg/mL for women) were associated with multivariable-adjusted HRs of 1.62 for death (p=0.02), 1.76 for a first major cardiovascular event, (p=0.03), 1.91 for atrial fibrillation (p=0.02), 1.99 for stroke or transient ischemic attack (p=0.02), and 3.07 for heart failure (p=0.002). However, any gains over use of conventional risk factors appear to be minimal.

Section Summary

None of the available evidence provides adequate data to establish that BNP improves outcomes when used in clinical care. Thus, given the uncertain impact on clinical outcomes, this testing is considered investigational.

Cystatin C

Ito et al evaluated the value of adding cystatin C to Framingham Risk Score (FRS) variables to predict cardiovascular disease risk in 6653 adults without clinical cardiovascular disease from the Multi-Ethnic Study of Atherosclerosis.(63) Cardiovascular risk prediction did not improve with the addition of cystatin C to FRSs. Lee et al conducted a meta-analysis of 14 studies consisting of 22,509 participants from predominantly high-cardiovascular-risk patients to evaluate the relationship between elevated cystatin C levels and cardiovascular disease risk.(64) Higher levels of cystatin C were associated with greater risk of cardiovascular disease (RR=2.62; 95% CI, 2.05 to 3.37; p<0.001), coronary heart disease (RR=1.72; 95% CI, 1.27 to 2.34; p<0.001), and stroke (RR=1.83; 95% CI, 1.12 to 3.00; p=0.02) after adjustment for known cardiovascular risk factors.

Section Summary

None of the available evidence provides adequate data to establish that cystatin C improves outcomes when used in clinical care. Thus, given the uncertain impact on clinical outcomes, this testing is considered investigational.

Fibrinogen

Kengne et al evaluated data from 9 prospective, community-based cohorts from the British and Scottish general population-based health surveys.(65) In the analysis of a total of 33,091 adults, 1006 of whom had diabetes, fibrinogen was found to be positively associated with a higher risk of cardiovascular disease by 34% (95% CI, 26% to 42%) and all-cause mortality by 30% (95% CI, 26% to 35%). The relationship with cardiovascular mortality and a higher fibrinogen produced HRs (95% CI) of 1.48 (1.21 to 1.81) in subjects with diabetes and 1.31 (1.23 to 1.39) in those without diabetes. The interaction between fibrinogen and cardiovascular disease risk was not significantly different between the diabetic and nondiabetic populations (p=0.47). Despite any improved predictive accuracy, the addition of fibrinogen to established risk factors was reported to not be clinically important.

Other studies have found an association between fibrinogen and cardiovascular risk including the EPIC- Norfolk cohort study66 and the Fibrinogen Studies Collaboration.(67,68) In a report from the Fibrinogen Studies Collaboration, it was noted that fibrinogen levels increased with age and were linked to established risk factors such as triglycerides, smoking and body mass index.(67)

Section Summary

None of the available evidence provides adequate data to establish that fibrinogen improves outcomes when used in clinical care. Thus, given the uncertain impact on clinical outcomes, this testing is considered investigational.

Leptin

Sattar et al reported on a prospective study of 5661 men and a systematic review of 7 prospective studies to evaluate the relationship between leptin and cardiovascular disease.(69) Leptin levels in the top third had an OR for coronary heart disease of 1.25 (95% CI, 0.96 to 1.62) compared with the bottom third. After adjusting for body mass index (BMI), this decreased to 0.98 (95% CI, 0.72 to 1.34) suggesting any association of leptin with cardiovascular disease is largely dependent on BMI.

Section Summary

None of the available evidence provides adequate data to establish that Leptin improves outcomes when used in clinical care. Thus, given the uncertain impact on clinical outcomes, this testing is considered investigational.

HDL Particle Size/Concentration

In the JUPITER RCT,(70) 10,886 patients without cardiovascular disease were randomized to rosuvastatin or placebo and followed for a median of 2 years. Before randomization and 1 year after, levels of LDL-C,

HDL-C, apo AI, and nuclear magnetic resonance (NMR) measured HDL size and HDL particle (HDL-P) numbers were evaluated. Statistically significant changes in the median and 25th and 75th percentile values of HDL measures between baseline and year 1 values occurred in the rosuvastatin and placebo groups for all levels (p<0.001) except for apo AI and HDL-P size in the placebo group, which were not significantly different (p=0.09 and 0.74, respectively). Changes in the rosuvastatin group were all
statistically significant when compared with placebo for LDL-C, HDL-C, apo AI, and HDL-P size and number (p<0.001 for all). In the placebo group, inverse associations with cardiovascular disease and HDL-C, apo AI, and HDL-P were seen. HDL-P number in the rosuvastatin group had a greater association with cardiovascular disease (HR=0.73; 95% CI, 0.57 to 0.93; p=0.01) than HDL-C (HR=0.82; 95% CI, 0.63 to 1.08; p=0.16) or apo AI (HR=0.86; 95% CI, 0.67 to 1.10; p=0.22). This association remained after adjusting for HDL-C (HR=0.72; 95% CI, 0.53 to 0.97; p=0.03). HDL size was not significantly associated with cardiovascular disease in risk factor‒adjusted models.

Current Treatment Guidelines

No guidelines were identified that specify a role for HDL subclass for the identification or management of cardiovascular disease.

Section Summary

One RCT has evaluated the association of HDL particle size and number as measured by NMR with residual cardiovascular disease risk. While this study found an association with HDL-P (but not HDL size) and cardiovascular disease, this does not demonstrate how NMR-measured HDL-P number would be used to change clinical management beyond information provided by traditional lipid measures. Therefore, there is no evidence that HDL size or HDL-P number measurement improves health
outcomes.

Based on the available evidence and the uncertain impact of testing on clinical outcomes, testing for HDL particle size or concentration is considered investigational.

LDL Subclass and LDL Particle Size/Concentration

LDL Subclass as an Independent Risk Factor for Cardiovascular Disease

A nested case-control study from the Physician’s Health Study, a prospective cohort study of approximately 15,000 men, investigated whether LDL particle size was an independent predictor of CAD risk, particularly in comparison to triglyceride levels.(71) This study concluded that while LDL particle diameter was associated with risk of myocardial infarction (MI), this association was not present after adjustment for triglyceride level. Only triglyceride level was significant independently.

The Quebec Cardiovascular Study10,72 evaluated the ability of “nontraditional” lipid risk factors, including LDL size, to predict subsequent CAD events in a prospective cohort study of 2155 men followed up for 5 years. The presence of small LDL was associated with a 2.5 times increased risk for ischemic heart disease after adjustment for traditional lipid values, indicating a level of risk similar to total LDL. This study also suggested an interaction in atherogenic risk between LDL size and apo B levels. In the presence of small LDL particles, elevated apo B levels were associated with a 6-fold increased risk of CAD, whereas when small LDL particles were not present, elevated apo B levels were associated with only a 2-fold increase in risk.

In 2005, Tzou et al examined the clinical value of “advanced lipoprotein testing” in 311 randomly selected adults participating in the Bogalusa Heart Study.(73)
Advanced lipoprotein testing consisted of subclass patterns of LDL, ie, presence of large buoyant particles, intermediate particles, or small dense particles. These measurements were used to predict the presence of subclinical atherosclerosis, as measured ultrasonographically by carotid intimal-media thickness. In multivariate logistic regression models, substituting advanced lipoprotein testing for corresponding traditional lipoprotein values did not improve prediction of the highest quartile of carotid intimal-media thickness.

LDL Subclass as a Predictor of Treatment Response

Patients with subclass pattern B have been reported to respond more favorably to diet therapy compared with those with subclass pattern A.(74) Subclass pattern B has also been shown to respond more favorably to the drugs gemfibrozil and niacin, with a shift from small, dense LDL particles to larger LDL particles. While statin drugs lower the overall concentration of LDL-C, there is no shift to the larger LDL particles.(75)

Superko et al(76) reported that the response to gemfibrozil differed in patients with LDL subclass A compared with those with LDL subclass B. There was a greater reduction in the small, low-density LDL levels for patients with subclass B, but this was not correlated with clinical outcomes. Another study reported that atorvastatin treatment led to an increase in mean LDL size, while pravastatin treatment led to a decrease in LDL size.(77)

These studies generally confirmed that small, dense LDL is impacted preferentially by fibrate treatment(78-80) and possibly also by statin therapy.(78,80) However, none of the studies demonstrate that preferentially targeting small, dense LDL leads to improved outcomes, compared with using the standard LDL targets that are widespread in clinical care.

Several trials with angiographic outcomes have examined the change in LDL particle size in relation to angiographic progression of CAD. The Stanford Coronary Risk Intervention Project (SCRIP) trial studied the relationship between small, dense LDL and the benefit of diet, counseling, and drug therapy in patients with CAD, as identified by initial coronary angiogram.(81) Patients with subclass pattern B showed a significantly greater reduction in CAD progression, compared with those with subclass pattern A. The Familial Atherosclerosis Treatment Study (FATS) randomized patients from families with premature CAD and elevated apo B levels.(82) Change in LDL particle size was significantly correlated with angiographic progression of CAD in this study. Fewer studies have evaluated clinical outcomes in relation to LDL
particle size. In the Cholesterol and Recurrent Events (CARE) trial, survivors of MI with normal cholesterol levels were randomly assigned to lipid-lowering therapy or placebo. A post hoc analysis from this trial failed to demonstrate a correlation between change in particle size and treatment benefit.(83)

Measurement of LDL Particle Size and Concentration by NMR

Similar to small dense lipoprotein particles, several epidemiologic studies have shown that the lipoprotein particle size and concentration measured by NMR is also associated with cardiac risk. For example, data derived from the Cardiovascular Health Study, Women’s Health Study, and PLAC-1 trial suggest that the number of LDL particles is an independent predictor of cardiac risk.(84-86) Translating these findings into clinical practice requires setting target values for lipoprotein number. Proposed target values have been derived from the same data set (ie, Framingham study) that was used to set the ATP III target goals for LDL-C. For example, the ATP III targets for LDL-C correspond to the 20th, 50th, and 80th percentile values in the Framingham Offspring Study, depending on the number of risk factors present. Proposed target goals for lipoprotein number correspond to the same percentile values, and LDL particle concentrations corresponding to the 20th, 50th, and 80th percentile are 1100 nmol/L, 1400 nmol/L, and 1800 nmol/L, respectively.(87)

Following publication of several clinical trials indicating benefit for intensive statin therapy with lowering of LDL goals beyond those recommended in the ATP III guidelines,(29) many experts recommend a further lowering of the target LDL-C from 100 mg/dL to 70 mg/dL in high-risk patients. These new, more aggressive targets of therapy create additional questions of how either measurements of either LDL concentration or LDL size can be used to improve patient management.

Mora et al(88) evaluated the predictive ability of LDL particle size and number measured by NMR in participants of the Women’s Health Study, a prospective cohort study of 27,673 women followed over an 11-year period. After controlling for nonlipid factors, LDL particle number was a significant predictor of incident cardiovascular disease, with an HR of 2.51 (95% CI, 1.91 to 3.30) for the highest, compared with the lowest quintile. LDL particle size was similarly predictive of cardiovascular risk, with an HR of 0.64 (95% CI, 0.52 to 0.79). When compared with standard lipid measures and apolipoproteins, LDL particle size and number showed similar predictive ability but were not superior in predicting cardiovascular events.

Rosenson and Underberg conducted a systematic review of studies on lipid-lowering pharmacotherapies in 2013 to evaluate changes in LDL particles pre- and  posttreatments.(89) Reductions in mean LDL particles occurred in 34 of the 36 studies evaluated. Percentage reductions of LDL particles in several statin studies were smaller than reductions in LDL-C. LDL particles and apo B changes were comparable in studies. The authors suggest the differences in LDL particle reductions with different lipid-lowering therapies demonstrate potential areas of residual cardiovascular risk that can be addressed with LDL particle (LDL-P) monitoring.

In 2014 Toth et al reported on an analysis of LDL-C and LDL-P levels and cardiovascular risk using commercial insurance and Medicare claims data on 15,569 high-risk patients from the HealthCore Integrated Research Database (HIRD).(90) For each 100 nmol/L increase in LDL-P level, there was a 4% increase in risk of a coronary heart disease event (HR=1.04; 95% CI, 1.02 to1.05; p<0.000). A comparative analysis, using 1:1 propensity score matching of 2094 patients from the LDL-C target cohort (LDL-C level <100 mg/dL without a LDL-P level) and a LDL-P target cohort (LDL-P <1000 nmol/L and LDL-C of any level) found a lower risk of coronary heart disease or stroke in patients who received LDL-P measurement and were presumed to have received more intensive lipid-lowering therapy (HR=0.76; 95% CI, 0.61 to 0.96; at 12 months). A comparison of smaller LDL-P target groups at 24 (n=1242) and 36 (n=705) months showed similar reductions in coronary heart disease and stroke (HR=0.78; 95% CI, 0.62
to 0.97 and HR=0.75; 95% CI, 0.58 to 0.97, respectively).

Current Treatment Guidelines

A 2008 consensus statement commented on the use of LDL-P number in patients with cardiometabolic risk.(30) This article comments on the limitations of the clinical utility of NMR measurement of LDL-P number or size, including lack of widespread availability. This article also comments that there is a need for more independent data confirming the accuracy of the method and whether its predictive power is consistent across various patient populations.

Section Summary

Small LDL size is 1 component of an atherogenic lipid profile that also includes increased triglycerides, increased apo B, and decreased HDL. Some studies have reported that LDL size is an independent risk factor for CAD, and others have reported that a shift in LDL size may be a useful marker of treatment response. However, the direct clinical application of measuring small, dense lipoprotein particles is still unclear. To improve outcomes, clinicians must have the tools to translate this information into clinical practice. Such tools for linking levels of small, dense LDL to clinical decision making, both in risk assessment and treatment response, are currently not available. Published data are inadequate to determine how such measurements should guide treatment decisions and whether these treatment decisions result in beneficial patient outcomes.

A relatively small number of studies have evaluated the predictive ability of LDL particle size and number as measured by NMR. These studies do not demonstrate that NMR-measured particle size and/or number offer additional predictive ability beyond that provided by traditional lipid measures. NMR measures have been proposed as indicators of residual cardiovascular risk in patients treated with statins who have met LDL goals, but there is no evidence that these measures improve health outcomes when used for this purpose.

Based on the available evidence and the uncertain impact of testing on clinical outcomes, testing for LDL subclass and LDL-P size/concentration is considered  investigational.

Lipoprotein A

Lipoprotein A as a Predictor of Cardiovascular Risk

Numerous prospective RCTs, cohort studies and systematic reviews have evaluated lipoprotein (a) (lp[a]) as a cardiovascular risk factor. The following are representative prospective trials drawn from the extensive literature on this topic.

The Emerging Risk Factors Collaboration published a patient-level meta-analysis of 37 prospective cohort studies enrolling 154,544 individuals.(9) Risk prediction was examined for a variety of traditional and nontraditional lipid markers. For lp(a), evidence from 24 studies on 133,502 subjects reported that lp(a) was an independent risk factor for reduced cardiovascular risk, with an adjusted HR for cardiovascular events of 1.13 (95% CI, 1.09 to 1.18). The addition of lp(a) to traditional risk factors resulted in a small improvement in risk prediction, with an increase in the C statistic of approximately 0.002. On reclassification analysis, there was no significant improvement in the net reclassification index (0.05%; 95% CI, -0.59 to 0.70).

A systematic review by Genser et al(91) included 67 prospective studies on 181,683 subjects that evaluated the risk of cardiovascular disease associated with lp(a). Pooled analysis was performed on 37 studies that reported the end points of cardiovascular events. When grouped by design and populations, the relative risks for these studies, comparing the uppermost and lowest strata of lp(a), ranged from 1.64 to 2.37. The risk ratio for cardiovascular events was higher in patients with previous cardiovascular disease compared with patients without previous disease. There were no significant associations found between lp(a) levels, overall mortality, or stroke.

The Lipid Research Clinics (LRC) Coronary Primary Prevention Trial, one of the first large-scale, RCTs of cholesterol-lowering therapy, measured initial lp(a) levels and reported that lp(a) was an independent risk factor for CAD when controlled for other lipid and nonlipid risk factors.(92) As part of the Framingham offspring study, lp(a) levels were measured in 2191 asymptomatic men between the ages of 20 and 54 years.(93) After a mean follow-up of 15 years, there were 129 coronary heart disease events, including MI, coronary insufficiency, angina, or sudden cardiac death. Comparing the lp(a) levels of these patients with the other participants, the authors concluded that elevated lp(a) was an independent risk factor for the development of premature coronary heart disease (ie, before age 55 years). The ARIC study evaluated
the predictive ability of lp(a) in 12,000 middle-aged subjects free of CAD at baseline who were followed up for 10 years.(14) The lp(a) levels were significantly higher among patients who developed CAD compared with those who did not, and lp(a) levels were an independent predictor of CAD above traditional lipid measures.

Several RCTs on lipid-lowering therapies have found lp(a) is associated with residual cardiovascular risk. In a subgroup analysis of 7746 white patients from the JUPITER study,(94) median lp(a) levels did not change in either group of patients randomized to treatment with rosuvastatin or placebo during a median 2-year follow-up. Lp(a) was independently associated with a residual risk of cardiovascular disease despite statin treatment (adjusted HR=1.27; 95% CI: 1.01 to 1.59, p=0.04). The LIPID RCT95 randomized 7863 patients to pravastatin or placebo. Patients were followed for a median 6 years. Lp(a) concentrations did not change significantly at 1 year. Baseline lp(a) concentration was associated with total coronary heart disease events (p<0.001), total cardiovascular disease events (p=0.002), and coronary events (p=0.03). The AIM-HIGH study,(96) lp(a) levels in 1440 patients at baseline and on simvastatin plus placebo or simvastatin plus extended-release niacin were significantly predictive of CV
events with HRs ranging from 1.18 to 1.25.

Kamstrup et al(97) analyzed data from the Copenhagen City Heart Study, which followed up 9330 subjects from the Copenhagen general population over a period of 10 years. This study reported a graded increase in risk of cardiac events with increasing lp(a) levels. At extreme levels of lp(a) above the 95th percentile, the adjusted HR for MI was 3.6 (95% CI, 1.7 to 7.7) for women and 3.7 (95% CI, 1.7 to 8.0) in men. Tzoulaki et al98 reported data from the Edinburgh Artery Study, which was a population cohort study that followed up 1592 subjects for a mean of 17 years. These authors reported that lp(a) was an independent predictor of MI, with an OR of 1.49 (95% CI, 1.0 to 2.2) for the highest one-third versus the lowest one-third.

Zakai et al(99) evaluated 13 potential biomarkers for independent predictive ability compared with established risk factors, using data from 4510 subjects followed up for 9 years in the Cardiovascular Health Study. The lp(a) was 1 of 7 biomarkers that had incremental predictive ability above established risk factors. The adjusted HR for each SD increase in lp(a) was 1.07 (95% CI, 1.0 to 1.12).

Some studies, however, have failed to demonstrate such a relationship. In the Physicians’ Health Study, initial lp(a) levels in the 296 participants who subsequently experienced MI were compared with lp(a) levels in matched controls who remained free from CAD.(100) The authors found that the distribution of lp(a) levels between the groups was identical. The European Concerted Action on Thrombosis and Disabilities (ECAT) study, a trial of secondary prevention, evaluated lp(a) as a risk factor for coronary events in 2800 patients with known angina pectoris.(101) In this study, lp(a) levels were not significantly different among patients who did and did not have subsequent events, suggesting that lp(a) levels were not useful risk markers in this population.

Some researchers have hypothesized that there is a stronger relationship between lp(a) and stroke than for coronary heart disease. Similar to the situation with cardiac disease, most prospective studies, but not all, have indicated that lp(a) is an independent risk factor for stroke. In 1 prospective cohort study, Rigal et al(102) reported that an elevated lp(a) level was an independent predictor of ischemic stroke in men (OR=3.55; 95% CI, 1.33 to 9.48) but not in women (OR=0.42; 95% CI, 0.12 to 1.26). In the ARIC prospective cohort study of 14,221 participants,(103) elevated lp(a) was a significant independent predictor of stroke in black women (RR=1.84; 95% CI, 1.05 to 3.07) and white women (RR=2.42; 95% CI, 1.30 to 4.53) but not in black men (RR=1.72; 95% CI, 0.86 to 3.48) or white men (RR=1.18; 95% CI, 0.47 to 2.90).

There also may be a relationship between lp(a) as a cardiovascular risk factor and hormone status in women. Suk Danik et al(104) reported the risk of a first cardiovascular event over a 10-year period in 27,736 women enrolled in the Women’s Health Study. After controlling for standard cardiovascular risk factors, lp(a) was an independent predictor of risk in women who were not taking hormonal replacement therapy (HR=1.77; 95% CI, 1.36 to 2.30; p<0.001). However, for women who were taking hormonal  replacement therapy, lp(a) levels were not a significant independent predictor of cardiovascular risk (HR=1.13; 95% CI, 0.84 to 1.53; p=0.18).

Several meta-analyses have also examined the relationship between lp(a) levels and cardiovascular risk. Bennet et al(105) synthesized the results of 31 prospective studies with at least 1 year of follow-up and that reported data on cardiovascular death and nonfatal MI. The combined results revealed a significant positive relationship between lp(a) and cardiovascular risk, with an OR for patients with lp(a) in the topthird compared with those in the bottom-third of 1.45 (95% CI, 1.32 to 1.58). This analysis reported a moderately high degree of heterogeneity in the included studies (I2 =43%), reflecting the fact that not all studies reported a significant positive association.

Smolders et al summarized evidence from observational studies on the relationship between lp(a) and stroke.(106) Five prospective cohort studies and 23 case-control studies were included in this meta-analysis. Results from prospective cohort studies, lp(a) added a modest amount of incremental predictive information (combined RR for the highest one-third of lp(a): 1.22; 95% CI, 1.04 to 1.43). From casecontrol studies, an elevated lp(a) level was also associated with an increased risk of stroke (combined
OR=2.39; 95% CI, 1.57 to 3.63).

A patient-level meta-analysis of 36 prospective studies published between 1970 and 2009 included 126,634 participants.(107) Overall, the independent association of lp(a) with vascular disease was consistent across studies but modest in size. The combined risk ratio, adjusted for age, sex, and traditional lipid risk factor, was 1.13 (95% CI, 1.09 to 1.18) for coronary heart disease and 1.10 (95% CI, 1.02 to 1.18) for ischemic stroke. There was no association of lp(a) levels with mortality.

Genetic studies have examined the association of various genetic loci with lp(a) levels, and Mendelian randomization studies have examined whether lp(a) is likely to be causative for CAD. In 1 such study,(108) there were 3 separate loci identified for increased lp(a) levels. Genetic variants were identified at 2 of these loci that were independently associated with coronary disease (OR=1.70; 95% CI, 1.49 to 1.95; OR=1.92; 95% CI, 1.48 to 2.49). This finding strongly implies that elevated lp(a) levels are causative of coronary disease, as opposed to simply being associated.

Lipoprotein A as Treatment Target

There is a lack of evidence to determine whether lp(a) can be used as a target of treatment. Several randomized studies of lipid-lowering therapy have included measurements of lp(a) as an intermediate outcome measurement. While these studies have demonstrated that lp(a) levels are reduced in patients receiving statin therapy, the data are inadequate to demonstrate how this laboratory test can be used to improve patient management.(109,110)

Section Summary

A large amount of epidemiologic evidence has determined that lp(a) is an independent risk factor for cardiovascular disease. The overall degree of risk associated with lp(a) levels appears to be modest, and the degree of risk may be mediated by other factors such as LDL levels and/or hormonal status. There is considerable uncertainty regarding the clinical utility of measuring lp(a), specifically how knowledge of lp(a) levels can be used in clinical care of patients who are being evaluated for lipid disorders. There is scant evidence on the use of lp(a) as a treatment target for patients with hyperlipidemia. The available evidence is insufficient related to impact on clinical outcomes; testing for lp(a) is considered investigational.

Summary of Evidence

Numerous nontraditional lipid and other biomarker measurements have been proposed for use in improving risk prediction for cardiovascular disease, including apolipoprotein B (apo B), apolipoprotein AI (apo AI), the ratio of apo B/apo AI, apolipoprotein E (apo E), lipoprotein A, subclasses of low-density lipoprotein (LDL) and high-density lipoprotein (HDL), B-type natriuretic peptide, cystatin C, fibrinogen and leptin. In general, there is evidence that some of these markers may provide some incremental accuracy in risk prediction. However, it has not been established that the incremental accuracy provides clinically important information beyond that of traditional lipid measures. Furthermore, no study has provided highquality evidence that measurement of markers leads to changes in management that improve health
outcomes.

Some markers, eg, apo B, have also been proposed as treatment targets for lipid-lowering therapy. While some evidence supports that they may be accurate in predicting residual risk for patients on lipid-lowering therapy, there is no high-quality evidence that these markers lead to health outcome improvements when used in place of traditional lipid targets, such as LDL. Because of the deficiencies in the literature around these issues, the use of these novel lipid risk markers remains investigational.

Practice Guidelines and Position Statements

The American College of Cardiology/American Heart Association published guidelines in 2013 for the assessment of cardiovascular risk.(111) Pooled cohort equations for estimating aterioscleratic cardiovascular disease (ASCVD) were developed from sex and race specific proportional hazards models that included covarieties of age, treated or untreated systolic blood pressure level, total cholesterol and HDL cholesterol levels, current smoking status, and history of diabetes. Additional risk factors that were
evaluated included diastolic blood pressure, family history of ASCVD, moderate or severe chronic kidney disease, and body mass index. None of these variables significantly improved discrimination for 10-year hard ASCVD risk prediction. Further research using state of the art statistical techniques (including net reclassification improvement and integrative discrimination index are needed to examine the utility of novel biomarkers when added to these new pooled cohort equations in different populations and patient subgroups.

The 2012 guidelines on cardiovascular disease prevention from the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice indicate apo B can be a substitute for LDL-C, but its use does not improve risk assessment and apo B is not readily available.(112) The use of lipoprotein (a) isn’t justified as a treatment target or for screening the general population.

The National Cholesterol Education Program Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) issued a position statement in 2001.1 Apo B, apo AI, lipid subclass, and lipoprotein (a) were listed as “emerging risk factors” for cardiovascular risk assessment, without specific recommendations for how these measures should be used in clinical practice. There was a 2004 update to these guidelines which discussed the result of clinical trials of statin therapy.(113)

A publication from a consensus conference of the American Diabetes Association and the American College of Cardiology Foundation(30) included specific recommendations for incorporating apo B testing into clinical care for high-risk patients. They recommended that for patients with metabolic syndrome who are being treated with statins, both LDL-C and apo B should be used as treatment targets, with an apo B target of less than 90 mg/dL. This consensus statement also commented on the use of LDL particle number in patients with cardiometabolic risk. They commented on the limitations of the clinical utility of NMR measurement of LDL-P number or size, including lack of widespread availability. They also mentioned that there is a need for more independent data confirming the accuracy of the method and whether its predictive power is consistent across various patient populations.

A Canadian task force has also endorsed use of apo B as a treatment target and proposed a target apo B level of 90 mg/dL.(31) These guidelines also recommended that a lipoprotein (a) concentration greater than 30 mg/dL with elevated LDL or other major risk factors may indicate the need for earlier and more intensive therapy to lower the LDL-C level.

U.S. Preventive Services Task Force Recommendations

The U.S. Preventive Services Task Force issued recommendations in 2009(114) on the use of nontraditional risk factors for the assessment of coronary heart disease. They included lipoprotein (a) in their summary statement that stated “The evidence is insufficient to assess the balance of benefits and harms of using the nontraditional risk factors discussed in this statement to screen asymptomatic men and women with no history of CHD to prevent CHD events”.

Medicare National Coverage
There is no national coverage determination (NCD). In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers.

References:

  1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. May 16 2001;285(19):2486-2497. PMID 11368702
  2. BlueCross and BlueShield Technology Evaluation Center. C-Reactive Protein as a Cardiac Risk Marker (Special Report). TEC Assessment. 2002;Volume 17, Tab 23. PMID
  3. Thanassoulis G, Williams K, Ye K, et al. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. J Am Heart Assoc. 2014;3(2):e000759. PMID 24732920
  4. van Holten TC, Waanders LF, de Groot PG, et al. Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. PLoS One. 2013;8(4):e62080. PMID 23630624
  5. Tzoulaki I, Siontis KC, Evangelou E, et al. Bias in associations of emerging biomarkers with cardiovascular disease. JAMA Intern Med. Apr 22 2013;173(8):664-671. PMID 23529078
  6. Willis A, Davies M, Yates T, et al. Primary prevention of cardiovascular disease using validated risk scores: a systematic review. J R Soc Med. Aug 2012;105(8):348-356. PMID 22907552
  7. Robinson JG, Wang S, Jacobson TA. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol. Nov 15 2012;110(10):1468-1476. PMID 22906895
  8. Sniderman AD, Islam S, Yusuf S, et al. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis. Dec 2012;225(2):444-449. PMID 23068583
  9. Di Angelantonio E GP, Pennells L, et al. Lipid-Related Markers and Cardiovascular Disease Prevention. JAMA. 2012;307(23):2499-2506. PMID
  10. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation. Aug 1 1996;94(3):273-278. PMID 8759066
  11. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. Dec 15 2001;358(9298):2026-2033. PMID 11755609
  12. Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. Jul 20 2005;294(3):326-333. PMID 16030277
  13. Benn M, Nordestgaard BG, Jensen GB, et al. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol. Mar 2007;27(3):661-670. PMID 17170368
  14. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. Sep 4 2001;104(10):1108-1113. PMID 11535564
  15. Rasouli M, Kiasari AM, Mokhberi V. The ratio of apoB/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease. Clin Chem Lab Med. 2006;44(8):1015-1021. PMID 16879071
  16. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med. Feb 2004;255(2):188-205. PMID 14746556
  17. Kappelle PJ, Gansevoort RT, Hillege JL, et al. Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein. J Intern Med. Feb 2011;269(2):232-242. PMID 21129046
  18. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. Feb 14 2007;297(6):611-619. PMID 17299196
  19. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. Aug 15 2007;298(7):776-785. PMID 17699011
  20. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. Mar 28 2012;307(12):1302-1309. PMID 22453571
  21. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. Aug 5 2014;64(5):485-494. PMID 25082583
  22. Ballantyne CM, Pitt B, Loscalzo J, et al. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial). Am J Cardiol. Feb 15 2013;111(4):506-509.
    PMID 23237107
  23. Gotto AM, Jr., Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. Feb 8 2000;101(5):477-484. PMID 10662743
  24. Simes RJ, Marschner IC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation. Mar 12 2002;105(10):1162-1169. PMID 11889008
  25. Kastelein JJ, van der Steeg WA, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. Jun 10 2008;117(23):3002-3009. PMID 18519851
  26. Mora S, Wenger NK, Demicco DA, et al. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. Apr 24 2012;125(16):1979-1987. PMID 22461416
  27. Mora S, Glynn RJ, Boekholdt SM, et al. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J Am Coll Cardiol. Apr 24 2012;59(17):1521-1528. PMID 22516441
  28. Snow V, Aronson MD, Hornbake ER, et al. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. Apr 20 2004;140(8):644-649. PMID 15096336
  29. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. Jul 13 2004;110(2):227-239. PMID 15249516
  30. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. Apr 2008;31(4):811-822. PMID 18375431
  31. Genest J, Frohlich J, Fodor G, et al. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ. Oct 28 2003;169(9):921-924. PMID 14581310
  32. Barter PJ, Ballantyne CM, Carmena R, et al. ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. Mar 2006;259(3):247-258. PMID 16476102
  33. Clarke R, Emberson JR, Parish S, et al. Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men. Arch Intern Med. Jul 9 2007;167(13):1373-1378. PMID 17620530 
  34. Birjmohun RS, Dallinga-Thie GM, Kuivenhoven JA, et al. Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation. Oct 30 2007;116(18):2029-2035. PMID 17923573
  35. van der Steeg WA, Boekholdt SM, Stein EA, et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med. May 1 2007;146(9):640-648. PMID 17470832
  36. Ray KK, Cannon CP, Cairns R, et al. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. Mar 2009;29(3):424-430. PMID 19122170
  37. Osei-Hwedieh DO, Amar M, Sviridov D, et al. Apolipoprotein mimetic peptides: Mechanisms of action as antiatherogenic agents. Pharmacol Ther. Apr 2011;130(1):83-91. PMID 21172387
  38. Mudd JO, Borlaug BA, Johnston PV, et al. Beyond low-density lipoprotein cholesterol: defining the role of lowdensity lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol. Oct 30 2007;50(18):1735-1741. PMID 17964036
  39. Sniderman AD, Kiss RS. The strengths and limitations of the apoB/apoA-I ratio to predict the risk of vascular disease: a Hegelian analysis. Curr Atheroscler Rep. Oct 2007;9(4):261-265. PMID 18173952
  40. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. Jan-Feb 1988;8(1):1-21. PMID 3277611
  41. Hallman DM, Boerwinkle E, Saha N, et al. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet. Aug 1991;49(2):338-349. PMID 1867194
  42. Koch W, Hoppmann P, Schomig A, et al. Apolipoprotein E gene epsilon2/epsilon3/epsilon4 polymorphism and myocardial infarction: case-control study in a large population sample. Int J Cardiol. Mar 28 2008;125(1):116-117. PMID 17433475
  43. Kulminski AM, Ukraintseva SV, Arbeev KG, et al. Health-protective and adverse effects of the apolipoprotein E epsilon2 allele in older men. J Am Geriatr Soc. Mar 2008;56(3):478-483. PMID 18179501
  44. Schmitz F, Mevissen V, Krantz C, et al. Robust association of the APOE epsilon4 allele with premature myocardial infarction especially in patients without hypercholesterolaemia: the Aachen study. Eur J Clin Invest. Feb 2007;37(2):106-108. PMID 17217375
  45. Vaisi-Raygani A, Rahimi Z, Nomani H, et al. The presence of apolipoprotein epsilon4 and epsilon2 alleles augments the risk of coronary artery disease in type 2 diabetic patients. Clin Biochem. Oct 2007;40(15):1150-1156. PMID 17689519
  46. Ciftdogan DY, Coskun S, Ulman C, et al. The association of apolipoprotein E polymorphism and lipid levels in children with a family history of premature coronary artery disease. J Clin Lipidol. Jan-Feb 2012;6(1):81-87. PMID 22264578
  47. Vasunilashorn S, Glei DA, Lan CY, et al. Apolipoprotein E is associated with blood lipids and inflammation in Taiwanese older adults. Atherosclerosis. Nov 2011;219(1):349-354. PMID 21840004
  48. de Andrade M, Thandi I, Brown S, et al. Relationship of the apolipoprotein E polymorphism with carotid artery atherosclerosis. Am J Hum Genet. Jun 1995;56(6):1379-1390. PMID 7762561
  49. Eichner JE, Kuller LH, Orchard TJ, et al. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol. Jan 15 1993;71(2):160-165. PMID 8421977
  50. Wilson PW, Myers RH, Larson MG, et al. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA. Dec 7 1994;272(21):1666-1671. PMID 7966894
  51. Wilson PW, Schaefer EJ, Larson MG, et al. Apolipoprotein E alleles and risk of coronary disease. A metaanalysis. Arterioscler Thromb Vasc Biol. Oct 1996;16(10):1250-1255. PMID 8857921
  52. Volcik KA, Barkley RA, Hutchinson RG, et al. Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. Am J Epidemiol. Aug 15 2006;164(4):342-348. PMID 16760224
  53. Bennet AM, Di Angelantonio E, Ye Z, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA. Sep 19 2007;298(11):1300-1311. PMID 17878422
  54. Ordovas JM, Mooser V. The APOE locus and the pharmacogenetics of lipid response. Curr Opin Lipidol. Apr 2002;13(2):113-117. PMID 11891412
  55. Sarkkinen E, Korhonen M, Erkkila A, et al. Effect of apolipoprotein E polymorphism on serum lipid response to the separate modification of dietary fat and dietary cholesterol. Am J Clin Nutr. Dec 1998;68(6):1215-1222. PMID 9846849
  56. Carmena R, Roederer G, Mailloux H, et al. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism. Jul 1993;42(7):895-901. PMID 8345800
  57. Chiodini BD, Franzosi MG, Barlera S, et al. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. Eur Heart J. Aug 2007;28(16):1977-1983. PMID 17567623
  58. Donnelly LA, Palmer CN, Whitley AL, et al. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenet Genomics. Apr 2008;18(4):279-287. PMID 18334912
  59. Vossen CY, Hoffmann MM, Hahmann H, et al. Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program. Clin Pharmacol Ther. Aug 2008;84(2):222-227.PMID 18388879
  60. Shaw LJ, Polk DM, Kahute TA, et al. Prognostic accuracy of B-natriuretic peptide measurements and coronary artery calcium in asymptomatic subjects (from the Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research [EISNER] study). Am J Cardiol. Nov 1 2009;104(9):1245-1250. PMID 19840570
  61. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. Jul 1 2009;302(1):49-57. PMID 19567439
  62. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. Feb 12 2004;350(7):655-663. PMID 14960742
  63. Ito H, Pacold IV, Durazo-Arvizu R, et al. The effect of including cystatin C or creatinine in a cardiovascular risk model for asymptomatic individuals: the multi-ethnic study of atherosclerosis. Am J Epidemiol. Oct 15 2011;174(8):949-957. PMID 21880578
  64. Lee M, Saver JL, Huang WH, et al. Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis. Circ Cardiovasc Qual Outcomes. Nov 2010;3(6):675-683. PMID 20923994
  65. Kengne AP, Czernichow S, Stamatakis E, et al. Fibrinogen and future cardiovascular disease in people with diabetes: aetiological associations and risk prediction using individual participant data from nine communitybased prospective cohort studies. Diab Vasc Dis Res. Mar 2013;10(2):143-151. PMID 22786872
  66. Ahmadi-Abhari S, Luben RN, Wareham NJ, et al. Seventeen year risk of all-cause and cause-specific mortality associated with C-reactive protein, fibrinogen and leukocyte count in men and women: the EPIC-Norfolk study. Eur J Epidemiol. Jul 3 2013. PMID 23821244
  67. Fibrinogen Studies C, Kaptoge S, White IR, et al. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant metaanalysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol. Oct 15 2007;166(8):867-879. PMID 17785713
  68. Fibrinogen Studies C, Danesh J, Lewington S, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. Oct 12 2005;294(14):1799-1809. PMID 16219884
  69. Sattar N, Wannamethee G, Sarwar N, et al. Leptin and coronary heart disease: prospective study and systematic review. J Am Coll Cardiol. Jan 13 2009;53(2):167-175. PMID 19130985
  70. Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation. Sep 10 2013;128(11):1189-1197. PMID 24002795
  71. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. Sep 18 1996;276(11):882-888. PMID 8782637
  72. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. Jan 7 1997;95(1):69-75. PMID 8994419
  73. Tzou WS, Douglas PS, Srinivasan SR, et al. Advanced lipoprotein testing does not improve identification of subclinical atherosclerosis in young adults: the Bogalusa Heart Study. Ann Intern Med. May 3 2005;142(9):742-750. PMID 15867406
  74. Kwiterovich PO, Jr. Clinical relevance of the biochemical, metabolic, and genetic factors that influence lowdensity lipoprotein heterogeneity. Am J Cardiol. Oct 17 2002;90(8A):30i-47i. PMID 12419479
  75. Superko HR. Beyond LDL cholesterol reduction. Circulation. Nov 15 1996;94(10):2351-2354. PMID 8921770
  76. Superko HR, Berneis KK, Williams PT, et al. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. Am J Cardiol. Nov 1 2005;96(9):1266-1272. PMID 16253595
  77. Sirtori CR, Calabresi L, Pisciotta L, et al. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin. Nutr Metab Cardiovasc Dis. Feb 2005;15(1):47-55. PMID 15871851
  78. Arca M, Montali A, Pigna G, et al. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia. Metabolism. Nov 2007;56(11):1534-1541. PMID 17950105
  79. Rosenson RS, Wolff DA, Huskin AL, et al. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care. Aug 2007;30(8):1945-1951. PMID 17483155
  80. Tokuno A, Hirano T, Hayashi T, et al. The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes. J Atheroscler Thromb. Jun 2007;14(3):128-132. PMID 17587764
  81. Miller BD, Alderman EL, Haskell WL, et al. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation. Nov 1 1996;94(9):2146-2153. PMID 8901665
  82. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. Nov 8 1990;323(19):1289-1298. PMID 2215615
  83. Campos H, Moye LA, Glasser SP, et al. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA. Sep 26 2001;286(12):1468-1474. PMID 11572739 
  84. Blake GJ, Otvos JD, Rifai N, et al. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. Oct 8 2002;106(15):1930-1937. PMID 12370215
  85. Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol. Jul 1 2002;22(7):1175-1180. PMID 12117734
  86. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol. Jul 15 2002;90(2):89-94. PMID 12106834
  87. Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol. Oct 17 2002;90(8A):22i-29i. PMID 12419478
  88. Mora S, Otvos JD, Rifai N, et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. Feb 24 2009;119(7):931-939. PMID 19204302
  89. Rosenson RS, Underberg JA. Systematic Review: Evaluating the Effect of Lipid-Lowering Therapy on Lipoprotein and Lipid Values. Cardiovasc Drugs Ther. Jul 28 2013. PMID 23893306
  90. Toth PP, Grabner M, Punekar RS, et al. Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. Atherosclerosis. Aug 2014;235(2):585-591. PMID 24956532
  91. Genser B, Dias KC, Siekmeier R, et al. Lipoprotein (a) and risk of cardiovascular disease--a systematic review and meta analysis of prospective studies. Clin Lab. 2011;57(3-4):143-156. PMID 21500721
  92. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. JAMA. Apr 6 1994;271(13):999-1003. PMID 8139085
  93. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA. Aug 21 1996;276(7):544-548. PMID 8709403
  94. Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. Feb 11 2014;129(6):635-642. PMID 24243886
  95. Nestel PJ, Barnes EH, Tonkin AM, et al. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arterioscler Thromb Vasc Biol. Dec 2013;33(12):2902-2908. PMID 24092750
  96. Albers JJ, Slee A, O'Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol. Oct 22 2013;62(17):1575- 1579. PMID 23973688
  97. Kamstrup PR, Benn M, Tybjaerg-Hansen A, et al. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. Jan 15 2008;117(2):176-184. PMID 18086931
  98. Tzoulaki I, Murray GD, Lee AJ, et al. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation. Apr 24 2007;115(16):2119-2127. PMID 17404162
  99. Zakai NA, Katz R, Jenny NS, et al. Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study. J Thromb Haemost. Jun 2007;5(6):1128-1135. PMID 17388967
  100. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. Nov 10 1993;270(18):2195-2199. PMID 8411602
  101. Bolibar I, von Eckardstein A, Assmann G, et al. Short-term prognostic value of lipid measurements in patients with angina pectoris. The ECAT Angina Pectoris Study Group: European Concerted Action on Thrombosis and Disabilities. Thromb Haemost. Dec 2000;84(6):955-960. PMID 11154140
  102. Rigal M, Ruidavets JB, Viguier A, et al. Lipoprotein (a) and risk of ischemic stroke in young adults. J Neurol Sci. Jan 15 2007;252(1):39-44. PMID 17113602
  103. Ohira T, Schreiner PJ, Morrisett JD, et al. Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. Jun 2006;37(6):1407-1412. PMID 16675734
  104. Suk Danik J, Rifai N, Buring JE, et al. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol. Jul 8 2008;52(2):124-131. PMID 18598891
  105. Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med. Mar 24 2008;168(6):598-608. PMID 18362252
  106. Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke. Jun 2007;38(6):1959-1966. PMID 17478739
  107. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. Jul 22 2009;302(4):412-423. PMID 19622820
  108. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. Dec 24 2009;361(26):2518-2528. PMID 20032323
  109. Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol. Mar 15 2003;91(6):667-672. PMID 12633795
  110. van Wissen S, Smilde TJ, Trip MD, et al. Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia. Heart. Aug 2003;89(8):893-896. PMID 12860867
  111. American College of Cardiology and American Heart Association. 2013 ACCF/AHA guideline for assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2013; http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437741.48606.98.full.pdf. Accessed July, 2014
  112. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. Jul 2012;33(13):1635-1701. PMID 22555213
  113. National Cholesterol Education Program (NCEP). ATP III Update 2004: Implications of ATP III recent clinical trials for ATP III guidelines. 2004; http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3upd04.htm. Accessed July, 2014.
  114. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med. Oct 6 2009;151(7):496-507. PMID 19805772

 

Codes

Number

Description

CPT 

 

See policy Guidelines

ICD-9 

 

Investigational for all diagnoses

ICD-10-CM (effective 10/1/15)    

Investigational for all diagnoses

ICD-10-PCS (effective 10/1/15)     Not applicable. No ICD procedure codes for laboratory tests.

Index

 


Policy History

 

Date Action Reason
06/10/10 New Policy New policy created by consolidating reference policies (noted below) with literature search through May 2010.  measurement of novel lipid risk factors (ie, apolipoprotein B, apolipoprotein AI, apolipoprotein E, LDL subclass, HDL subclass, lipoprotein[a]) is considered investigational as an
adjunct to LDL cholesterol in the risk assessment and management of cardiovascular disease. (Consolidated Policies 2.04.12 (LDL particles), 2.04.20 (apoB), 2.04.21 (lp[a]), 2.04.24 (HDL subclass; apo A1), 2.04.25 (apo E) are no longer part of MPRM.)
06/09/11 Replace policy; coding correction only Added Policy Guidelines information on lipoprotein(a) and apolipoprotein E coding.
07/14/11 Replace policy Policy updated with literature review. No change to current policy statement. References 10, 25, 69, and 86-87 added to the policy.
7/12/12 Replace policy Policy updated with literature review. No change to current policy statement. References 3, 17-19, and 38-39 added to the policy.
12/13/12 Replace policy;coding update only Added 81401 to Policy Guidelines for APOE common variant testing.
9/12/13 Replace policy Policy updated with literature review through July 2013. B-type natriuretic protein, cystatin C, fibrinogen and leptin added to policy statement as investigational. Policy statement added indicating the use of panels that include lipid and non-lipid biomarkers would be considered not medically necessary. Title changed to Novel biomarkers in Risk Assessment and Management of Cardiovascular Disease. References 3-7, 20, 58-67, 86, and 105 added to the policy.
12/12/13 Replace policy;correction only Policy statement about panel testing deleted. Cross reference to new panel policy added.
9/11/14 Replace policy Policy updated with literature review through August 21, 2014. No change to current policy statement. References 3, 21, 70, 90, and 94-96 added to the policy. Reference 111 updated.